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Abstract
Ca
2+/calmodulin-dependent protein kinase II dB (CaMKIIdB) is one of the predominant isoforms of CaMKII in the heart. The
precise role of CaMKIIdB in the transcriptional cross-talk of Ca
2+-handling proteins during heart failure remains unclear. In
this work, we aim to determine the mechanism of CaMKIIdB in modulating the expression of sarcolemmal Na
+–Ca
2+
exchange (NCX1). We also aim to address the potential effects of calmodulin antagonism on the imbalance of NCX1 and
sarcoendoplasmic reticulum Ca
2+ ATPase (SERCA) during heart failure. Eight weeks after transverse aortic constriction (TAC)-
induced heart failure in mice, we found that the heart weight/tibia length (HW/TL) ratio and the lung weight/body weight
(LW/BW) ratio increased by 59% and 133%, respectively. We further found that the left ventricle-shortening fraction
decreased by 40% compared with the sham-operated controls. Immunoblotting revealed that the phosphorylation of
CaMKIIdB significantly increased 8 weeks after TAC-induced heart failure. NCX1 protein levels were also elevated, whereas
SERCA2 protein levels decreased in the same animal model. Moreover, transfection of active CaMKIIdB significantly
increased NCX1 protein levels in adult mouse cardiomyocytes via class IIa histone deacetylase (HDAC)/myocyte enhancer
factor-2 (MEF2)-dependent signaling. In addition, pharmacological inhibition of calmodulin/CaMKIIdB activity improved
cardiac function in TAC mice, which partially normalized the imbalance between NCX1 and SERCA2. These data identify
NCX1 as a cellular target for CaMKIIdB. We also suggest that the CaMKIIdB-induced imbalance between NCX1 and SERCA2 is
partially responsible for the disturbance of intracellular Ca
2+ homeostasis and the pathological process of heart failure.
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Introduction
Ca
2+/calmodulin-dependent protein kinase II (CaMKII) is
involved in the development of cardiac hypertrophy and
heart failure. Predominant expression of the CaMKIId isoform
contributes to cardiac decompensation by enhancing the ryano-
dine receptor (RyR)-mediated sarcoplasmic reticulum (SR) Ca
2+
leak, and attenuating CaMKIId activation has been shown to
limit the progression to heart failure [1–2]. CaMKIId regulates a
number of key proteins, including phospholamban (PLB), RyRs,
and the L-type channels, which are involved in intracellular Ca
2+
homeostasis [1–4]. As one of the two primary splicing variants of
the d isoform in the heart of many mammals, CaMKIIdB localizes
to the nucleus and is predicted to play a predominant role in Ca
2+-
mediated transcriptional gene regulation. Transient expression of
CaMKIIdB induces hypertrophy and ANF production in neonatal
rat ventricular myocytes [5]. The over-expression of CaMKIIdB
in transgenic mice has been shown to induce hypertrophy-related
gene expression and result in cardiac hypertrophy [5,6]. However,
little is known about the relationship between aberrant CaM-
KIIdB expression and the cross talk of Ca
2+-handling proteins
during heart failure.
In the physiological context, the depolarization of an action
potential activates L-type Ca
2+ channels and increases Ca
2+ influx
in the heart. This triggers the release of more Ca
2+ from the
sarcoendoplasmic reticulum Ca
2+-ATPase (SERCA2) via RyRs, an
event typically referred to as Ca
2+-induced Ca
2+ release. Dur-
ing relaxation, Ca
2+ is immediately transported into the SR via
SERCA2 and extruded by sarcolemmal Na
+–Ca
2+ exchange
(NCX1) in cardiomyocytes [7]. Features of a failing heart include a
prolonged action potential and depressed contractility, because
Ca
2+ overload has substantial, adverse effects in failing hearts.
Several investigators have shown that during heart failure, the
expression and activity of the Ca
2+-sequestering SERCA2 is
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protein levels of NCX1 are increased [8–11]. A study by
Andersson et al. showed that inducible cardiomyocyte-specific
excision of the Serca2 gene leads to a substantial reduction in
diastolic function in mice [12]. Over-expression of SERCA2a
improves the contraction performance of cardiomyocytes in
adrenergically stimulated adult rats [13]. As another essential
regulator of Ca
2+ homeostasis, NCX1 is reported to be up-
regulated at the transcriptional level during cardiac hypertrophy,
ischemia, and failure [9,14]. Meanwhile, Muller et al. demonstrat-
ed that the feline 1831Ncx1 H1 promoter is sufficient for the up-
regulation of Ncx1 in response to pressure overload in transgenic
mice [15]. These observations suggest that reduced SERCA
function and enhanced NCX1 function are associated with cardiac
dysfunction in mammalian heart failure. However, the question
arises as to whether CaMKIIdB can modulate the transcriptional
cross-talk and balance the expression of Ca
2+-handling proteins in
a failing heart. Accordingly, we tested the hypothesis that heart
failure induced by transverse aortic constriction (TAC) is
associated with an increase in CaMKIIdB activity, an imbalance
of Ca
2+-handling proteins and altered Ca
2+ homeostasis.
To better understand the molecular basis of aberrant Ca
2+
handling during heart failure, we sought to determine the potential
role of CaMKIIdB in modulating both the expression of NCX1
and NCX1/SERCA2 balance during the pathological process of
heart failure. Here, we demonstrate a correlation between the
activation of CaMKIIdB and the elevation of NCX1 protein levels
during TAC-induced heart failure in mice. The over-expression of
CaMKIIdB led to an increase in NCX1 expression and a
disturbance of the NCX1/SERCA2 balance via class IIa histone
deacetylase (HDACs)/myocyte enhancer factor-2 (MEF2)-depen-
dent signaling. Moreover, treatment with a calmodulin antagonist
improved cardiac function and normalized the NCX1/SERCA2
balance away from heart failure. These findings not only define a
novel function for CaMKIIdBi nC a
2+-handling proteins but also
highlight the potential therapeutic benefits of a novel calmodulin
antagonist against heart failure.
Materials and Methods
Animals
Adult male DDY mice weighing 35–40 g were obtained from
Nippon SLC (Hamamatsu, Japan). Eight-week-old males were
acclimated to the local environment for 1 week, which included
housing in polypropylene cages at 2361uC in a humidity-
controlled environment maintained on a 12-h light–dark schedule
(lights on 8:00 a.m. – 8:00 p.m.). Mice were provided food and
water ad libitum. All the animal experiments were carried out in
accordance with the National Institute of Health guidance for the
care and use of laboratory animals, were approved by The
Committees for Animal Experiments in Tohoku University in
Japan (21–252) and Zhejiang University in China (SCXK 2007–
0029).
Surgical procedure and drug treatment
Transverse aortic constriction (TAC) was performed on mice as
described previously [16–17]. Two weeks after the TAC or sham
surgery, mice were orally administered either a vehicle or DY-
9836 (10 or 20 mg/kg) daily for another 6 weeks. Mice were
decapitated 8 weeks after TAC, and the heart was dissected out for
further analysis. In addition, the mortality rate of TAC mice was
addressed using Kaplan-Meier survival plots.
Histological examination
Mouse heart samples were cut into transverse sections and
stained with hematoxylin and eosin (H&E) as described previously
[16]. Cross-sectional images of cardiomyocytes were scanned at
4006 magnification to evaluate the extent of cardiomyocyte
hypertrophy.
Measurement of cardiac hypertrophy
After 6 weeks of drug administration (DY-9836, 20 mg/kg), the
mice were sacrificed by cervical dislocation; then, the hearts and
lungs were removed and weighed as previously described [16].
Relative heart weights (HW), tibia length (TL) and lung weights
(LW) were calculated as ratios with body weight (HW/TL and
LW/BW), and cardiac geometry (wall thickness and chamber
diameter) was determined, which were used to estimate the degree
of cardiac hypertrophy.
Transthoracic echocardiography
Non-invasive echocardiographic measurements were performed
using ultrasonic diagnostic equipment (Aloka, SSD-6500, Tokyo,
Japan) as described previously [16].
Western blot analysis
All animals were sacrificed after 6 weeks of drug administration,
and their hearts were immediately harvested and stored at 280uC
until immunoblotting analyses were performed, as described
previously [17]. The following antibodies were used: NCX1 mouse
monoclonal antibody and MEF2 rabbit polyclonal antibody
(1:1000, Santa Cruz Biotechnology, Inc.), phospho-phospholamban
(Thr-17; 1:1000, Santa Cruz Biotechology, Santa Cruz, CA, and
Ser-16; 1:1000, Upstate, Lake Placid, NY), SERCA2 mouse
monoclonal antibody (1:1000, Sigma, St. Louis, MO), isoforms 1–
4 of CaMKII rabbit polyclonal antibody (1:500, Trans Genic Inc.),
HDAC4 (1:1000, Abcam, Cambridge, UK), active caspase-3
polyclonal antibody (1:500, Cell Signaling Technology) and b-
tubulin antibody (1:10000, Sigma, St. Louis, MO).
Adult cardiomyocyte cell culture and small interfering
RNA transfection
Adult mice cardiomyocytes were isolated as described previ-
ously [18]. Adult cardiomyocytes were transfected with activated
CaMKIIdB (T278D), dominant negative CaMKIIdB (K43E),
MEF2c siRNA, or control siRNA, as described previously [19].
After 24 h, a new serum-free DMEM supplement with endothelin-
1 (ET, 100 nM) was added, and the cells were incubated for
another 24 h.
Immunohistochemistry studies
Confocal immunocytochemical imaging was performed as
previously described [16]. For immunolabeling, sections were
incubated with a CaMKII 1–4 rabbit polyclonal antibody (1:100);
troponinT and HDAC4 mouse monoclonal antibody (1:100,
Abcam, Cambridge, UK); NCX1 mouse monoclonal antibody
(1:100, Santa Cruz Biotechnology, Inc.); a-actinin and active
caspase-3 polyclonal antibody (1:200, Cell Signaling Technology).
To label the cell nuclei (blue), 49-6-Diamidino-2-phenylindole
(DAPI, Sigma, St. Louis, MO) and TO-PRO3 (Invitrogen) was
used as a counterstain.
Chromatin immoprecipitation (ChIP)
ChIP assay was performed on MEF2 in the NCX1 promoter
region using a ChIP kit (Pierce, Thermo Scientific, Rockford, IL)
according to manufacturers’ protocol. Briefly, cardiac cells were
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tion, lysed in lysis buffer, and micrococcal nuclease digestion
(MNase digestion). Protein-DNA complexes were immunoprecip-
itated using MEF2 antibody (Santa Cruz Biotechology, Santa
Cruz, CA) or IgG as a control. MEF2/DNA formaldehyde cross-
linkages were reversed by heating at 65uC for 2 h, DNA purified
by DNA Clean-Up Column and resuspended in 50 ml of DNA
Column Elution Solution. PCR was performed using 1:10 dilution
of input chromatin (input DNA) or immunoprecipitated chroma-
tin (IP DNA). NCX1 primers sequences were forward 59- TT-
CGGCTTTCGCTTCC ATACA-39 and reverse 59- CTCTGG-
CCTTCTGCTTTTCCT-39. PCR conditions included: an initial
2 min denaturation at 94uC followed by 40 cycles of 94uC for 30 s,
55uC for 30 s and 72uC for 30 s; a final 5 min elongation at 72uC.
Luciferase assays
Small interfering RNAs (siRNAs) against MEF2 and control
siRNA were obtained from Santa Cruz Biotechnology. siRNAs
were introduced into cardiomyocytes with transfection medium
according to the manufacturer’s instructions. After 6 h incubation,
the fresh serum-free DMEM was changed, and then cells were
transiently transfected with 0.3 mg/well of pGL3-NCX1 reporter
construct using Lipofectamine 2000 (Invitrogen). For co-transfec-
tions, pRL-TK (Promega) encoding Renilla luciferase (Rluc)
served as an internal control. 0.3 mg/well of pGL3-NCX1 reporter
construct was transfected along with activated FLAG-tagged
CaMKIIdB (CaMKIIdB-T287D). After transfection for 24 h, ET
(100 nM) was added to the serum-free DMEM and cultures were
incubated for another 24 h. Firefly and Renilla luciferase activities
were measured using the Dual-Luciferase Reporter Assay System
(Promega) with a luminometer (GENG LIGHT 55, Yamato
Scientific Co., Ltd, Tokyo, Japan).
Measurement of intracellular Ca
2+ in adult
cardiomyocytes using Fura-2AM
Adult mice cardiomyocytes were isolated as described previously
[18]. The isolated cells were cultured with 10% FBS in DMEM for
24 h in a 35 mm dish. After incubation overnight, the cells were
loadedwithFura-2AMasdescribed previously[17].Theamplitude
of the caffeine-induced Ca
2+ transient was used as an index of SR
Ca
2+ content. Changes in the caffeine-induced Ca
2+ release from
theSR were determined usinga ratio ofthefluorescenceemissionat
510 nm in response to excitation at 340 and 380 nm.
TUNEL assay
In situ DNA fragmentation was assessed using a TUNEL assay
as previously described [20]. Images were recorded after
counterstaining with TO-PRO3 (nuclei marker), and cardiac
myocytes were identified by staining with anti-sarcomeric actinin
(green). The apoptotic index was determined by the number of
TUNEL positive cardiac muscle cells/the total number of nuclei
counted 6100% from a total of 60 fields per slide.
Statistical analyses
Differences between groups were assessed with Student’s t-test
and one-way ANOVA. Survival was expressed by the Kaplan-
Meier method, and survival curves were compared by the log-rank
test. All values are expressed as mean 6 S.E.M. A value of P,0.05
was considered statistically significant.
Results
Changes in CaMKIId, NCX1 and SERCA proteins following
TAC
We first determined the changes in immunoreactive Ca
2+-
handling proteins by Western blot (Fig. 1A and 1B). Compared
with the controls, phosphorylation of both CaMKIIdB and
CaMKIIdC were increased (3.1-fold and 2.8-fold, respectively).
Alterations in SERCA2 and NCX1 expression are thought to be
involved in the pathological process of heart failure [8–11].
Consistent with this idea, our results demonstrate that the
expression levels of SERCA2 and NCX1 were changed, but in
opposite directions, following TAC treatment. SERCA2 protein
levels decreased by 40% in the TAC group (Fig. 1A and B), and
NCX1 protein levels increased by nearly 2-fold (Fig. 1A and 1B).
Moreover, the localization of and changes in NCX1 expression for
TAC animals and control hearts were examined by immunohis-
tochemical studies (Fig. 1C). The dual staining of NCX1 and
troponinT confirmed that both of these proteins are present at the
same location in rat cardiomyocytes, in addition, increased
expression of NCX1 was also observed in TAC mice (Fig. 1C).
Active CaMKIIdB transfection up-regulates NCX1
expression in cultured cardiomyocytes
To determine the potential role of CaMKIIdB in the protein
expression of NCX1, we constructed an expression plasmid
encoding for the constitutively active CaMKIId3 mutant [active
CaMKIIdB (T287D)]. In cardiomyocytes, transfection with active
CaMKIIdB led to enriched NCX1 in the membrane, as shown in
the immunochemistry assay (Fig. 2A). In addition, as shown in the
immunoblot, these cells exhibited a 2.7-fold increase in NCX1
protein expression versus the control cells that were transfected
with an empty plasmid (Fig. 2B).
MEF2 participates in ET-induced NCX1 protein expression
As Ca
2+/calmodulin signaling has been shown to regulate
MEF2/HDAC function, we explored the possibility that CaM-
KIIdB also plays a role in regulating NCX1 expression via the
MEF2-mediated pathway. First, we tested the efficacy of MEF2c
siRNA to knockdown MEF2C in cultured adult cardiomyocytes in
the presence of ET (100 nM). Transfection withMEF2c siRNA
(300 ng/ml) almost completely inhibited MEF2 protein expres-
sion, as measured by Western blot analysis (Fig. 2C). We then
examined the efficacy of MEF2c siRNA on the protein levels of
NCX1 in the same context. Transfection with MEF2c siRNA
significantly attenuated ET-induced NCX1 expression, whereas
the control siRNA had no effect (Fig. 2C).
Furthermore, to determine if MEF2 is bound to the NCX1
promoter, we performed chromatin immunoprecipitation using
anti-MEF2 antibodies to collect MEF2/DNA complexes from
cultured cardiomyocytes (Fig. 2D). We established that the MEF2
antibody recognized formaldehyde fixed and MNase digested
MEF2/DNA complexes and that input DNA was similar in all
samples (Fig. 2D). DNA associated with the immunoprecipitation
reactions was purified. We found NCX1 promoter DNA was
amplified in cultured cardiomyocytes samples incubated with anti-
MEF2 antibody, but not in no-antibody control reactions (Fig. 2D).
The data suggest MEF2 protein binds to NCX1 promoter DNA.
To further test whether MEF2 can regulate NCX1 expression,
cultured cardiomyocytes were co-transfected with a reporter
plasmid carrying the human NCX1 promoter driving luciferase
expression (NCX1-Luc) and MEF2 siRNA vectors. The ET
treatment produced a more than a 5-fold increase in reporter
activity, whereas the MEF2 siRNA resulted in significant
decreasing (Fig. 2E). Co-transfection with a vector expressing
constitutively active CaMKII increased activity of the NCX1-Luc
reporter. Conversely, co-transfection with MEF2 siRNA expres-
sion vectors decreased active CaMKIIdB (T287D)-mediated
activation of the NCX1-Luc reporter (Fig. 2E).
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translocation are blocked by a calmodulin antagonist
We previously reported on the cardioprotective effects of
calmodulin antagonists, DY-9760e and DY-9836, in vitro and in
vivo through inhibition of Ca
2+/CaM-dependent enzymes via
downstream targets during the pathological process of cardiac
hypertrophy [19–20]. In the present study, our data demonstrate
that the ventricular cavity was larger than those in sham animals,
and the wall of the ventricle had thinned 8 weeks after TAC
(Fig. 3A and 3B). The wall thickness in TAC mice subjected to
DY-9836 (20 mg/kg) treatment was significantly decreased when
the animals were tested 8 weeks after the final treatment (Fig. 3A
Figure 1. Changes in CaMKIId, NCX1 and SERCA2 protein levels following TAC. (A) A representative image (upper) and bar graph (lower)
showing the results of immunoblotting with anti-CaMKII, anti-NCX1 and anti-SERCA2 antibodies. b-tubulin was used as the loading control.
(B) Densitometry values were normalized to the average of all sham values, which corresponded to 100% (mean 6 SEM, n=6).
**P,0.01,
***P,0.001
vs. sham-operated mice. (C) The representative confocal images of dual staining with anti-NCX1 (green fluorescence) and anti-troponinT (red
fluorescence) antibodies in TAC animals or control heart tissue. DAPI was used as a counterstain, to label the cell nuclei (blue). Scale bar=20 mm.
doi:10.1371/journal.pone.0024724.g001
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active CaMKIIdB (T278D), or DNCaMKIIdB (K43E) for 48 h, cardiomyocytes were harvested for immunochemistry and immunoblotting assays. (A)
Transfection with active CaMKIIdB enriched NCX1 in the membrane, as measured by an immunochemistry assay. (B) Detection of NCX1 protein
levels in the control and CaMKIIdB-over-expressing cardiomyocytes. A representative image (upper) and bar graph (lower) showing the results of
immunoblotting with the anti-NCX1 antibody. b-tubulin was used as the loading control.
**P,0.01 vs. cells transfected with an empty vector;
##P,0.01 vs. cells transfected with active CaMKII. (C) MEF2c silencing inhibits NCX1 protein expression in ET-treated cardiomyocytes. The cultured
cardiomyocytes were transfected with 1 mM of MEF2c-targeting siRNA (siRNA MEF2c) or an siRNA negative control (siRNA control), with or without ET
treatment. Cell lysates were collected 48 h after transfection and probed with the MEF2c polyclonal antibody. A representative image and bar graph
showing the results of immunoblots for NCX1 protein (upper). The quantitative analysis of protein levels was performed by densitometry of control,
siRNA control, and siRNA MEF2c cells (lower).
*P,0.05,
**P,0.01 vs. cells transfected with an empty vector;
##P,0.01 vs. ET treatments. (D)
Chromatin immunoprecipitation using anti-MEF2 antibodies. The MEF2/DNA complex was amplified using NCX1 promoter-specific primers. Negative
controls included all reagents except DNA. DNA size markers are included on the left. The arrow points to the amplified NCX1 DNA on the right. An
input sample was used as a control. 1: con, 2: ET, 3: ET+siRNAcon, 4: ET+siRNA MEF2c. (E) Luciferase activity was measured 24 h after co-transfection
with NCX1-Luc, siRNAcon, siRNA MEF2c with or without ET (or active CaMKII plasmid) treatment.
***P,0.001 vs. cells transfected with NCX1-Luc;
##P,0.01 vs. ET treatments;
$$P,0.01 vs. cells transfected with active CaMKII.
doi:10.1371/journal.pone.0024724.g002
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chamber diameter for DY-9836-treated mice as compared with
the TAC animals. To corroborate these results, we also assessed
the impact of CaMKIIdB alterations on SR Ca
2+-handling
proteins. As shown in Fig. 1, phosphorylation of CaMKIIdB/C
increased significantly during TAC-induced heart failure. Treat-
ment with DY-9836 significantly inhibited TAC-induced
phosphorylation of CaMKIIdB/C (Fig. 3C). We also examined
whether CaMKII regulated the nuclear-to-cytoplasmic shift
of HDAC4, a major CaMKIIdB downstream target. Western
blotting was used to quantify changes in the nuclear/cytosolic ratio
of HDAC4 (Fig. 3D). Our data showed that HDAC4 and
CaMKIIdB dramatically translocated from the nucleus to the
cytosol 8 weeks after TAC, whereas HDAC4 and CaMKIIdB
were primarily localized to the nucleus in sham animals. Notably,
the inhibition of calmodulin partially blocked the TAC-induced
nuclear-to-cytoplasmic translocation of HDAC4 (Fig. 3D). Ad-
ditionaly, we also found that HDAC4 inhibitor trichostatin A
decreases ET-induced NCX1 protein expression (Fig.S1).
Aberrant expression levels of SERCA2 and NCX1
following TAC are both inhibited by a calmodulin
antagonist
To gain further insight into the mechanisms of the NCX1/
SERCA imbalance in a TAC-induced failing heart, the effects of a
calmodulin antagonist on alterations of SERCA2 and NCX1 were
examined 8 weeks following TAC treatment. SERCA2 protein
levels were decreased in the TAC-treated animals (Fig. 4A),
whereas NCX1 protein levels were increased in same context
(Fig. 4B). In contrast, treatment with DY-9836 significantly
reversed the down-regulation of SERCA2 and the up-regulation
of NCX1 (Fig. 4). Additionally, our data show that NCX over-
expression induced by endothelin is associated with CaMKIIdB
phosphorylation and blocked by a CaMKII inhibitor (KN93) (Fig.
S1). In the present study, TAC-induced, dephosphorylated
phospholamban (either at Ser16 or Thr17) is tightly associated
with SERCA2a down-regulation, which is partially blocked by the
pharmacological inhibition of calmodulin (Fig. S2).
Changes in SR Ca
2+ content following TAC injury were
blocked by calmodulin inhibition
To verify the pathological relevance of CaMKIIdB over-
expression and Ca
2+-handling proteins after TAC treatment, we
measured the Ca
2+ content in the SR by assessing caffeine-induced
Ca
2+ release in cultured adult cardiomyocytes. The Fura-2 ratio at
340/380 nm was not significantly different between the three
groups at the baseline. When Ca
2+ release from the SR was
triggered by the application of 10 mM caffeine, transient Ca
2+
elevation was significantly decreased in the TAC group (Fig. 4C
and 4D). As shown in Figures 4C and 4D, the integrative volume
of the Ca
2+ transient in the DY-9836 treated group increased
significantly compared with the TAC group. DY-9836 treatment
alone (20 mg/kg) did not affect basal Ca
2+ levels or caffeine-
induced Ca
2+ release (data not shown).
Effect of calmodulin inhibition on TAC-induced
cardiomyocyte apoptosis
Cardiac apoptosis contributes to the phenotypic changes
associated with heart failure. Changes in apoptosis after 8 week
of TAC was detected by TUNEL assay. Images of TUNEL were
recorded as described in Materials and methods after counter-
staining with TO-PRO3 and alpha-actinin (Fig. 5A). Our results
suggest that the number of TUNEL-positive nuclei in TAC
animals increased by 4.3-fold versus the control group. In contrast,
chronic treatment with DY-9836 (20 mg/kg) significantly de-
creased TAC-induced apoptosis in mice (Fig. 5A and 5B).
Repeated treatment with DY-9836 (20 mg/kg for 6 weeks) alone
had no apparent effect on apoptosis in sham-operated animals
(data not shown). Confocal microscopic images of double staining
with anti-active caspase-3 (green fluorescence) and anti-troponinT
(red fluorescence) antibodies in the heart tissue, indicating that the
predominant activation of caspase-3 occurred in TAC mice. The
appearance of active caspase-3 in the heart tissue was largely
abolished by treatment with DY-9836 (Fig. 5C). The same result
also observed in Western blot experiment (Fig. S3)
Effect of calmodulin inhibition on cardiac function and
survival rate
Eight weeks after TAC, the treated mice had developed
cardiac hypertrophy, as measured by an increased HW/TL ratio
compared with the sham group (Fig. 6A). TAC also caused a
marked lung edema, demonstrated as a 133% increase in the
relative LW/BW ratios. TAC resulted in a significantly greater
decrease of fractional shortening than sham group. Notably, TAC-
induced changes in the HW/TL and LW/BW ratios and the
ejection fraction were inhibited by DY-9836 (20 mg/kg) treatment
(Fig. 6A, Table S1). Figure 6B illustrates the dramatic increase in
the mortality rate of TAC mice, which was assessed using Kaplan-
Meier survival plots. Repeated treatment with DY-9836 (20 mg/
kg for 6 weeks) had no effect on sham animals,but markedly
decreased mortality to a survival rate of 60% in TAC animals
(Log- rank test for mortality=6.17 (chi square, 1 df), P,0.05), as
observed at 64 days. The reduced mortality in response to DY-
9836 treatment suggests that the maintenance of Ca
2+ homeostasis
protects the heart from cardiac injury under TAC pathological
conditions.
Discussion
We can draw several conclusions from the present study, as
follows: 1) aberrant CaMKIIdB expression is associated with a
disturbance in SR Ca
2+ content and an imbalance of NCX1/
SERCA2 in TAC-induced heart failure; 2) active CaMKIIdB up-
Figure 3. TAC-induced CaMKIIdB activation and CaMKII-HDAC4 complex translocalization are blocked by a calmodulin antagonist.
(A) Representative hearts (upper) and H&E staining of heart tissues (lower) in mice treated with either a TAC or TAC+ calmodulin antagonist (DY-9836,
20 mg/kg for six weeks). Scale bar=50 mm. (B) The quantitative analyses of wall thickness (upper) and chamber diameter (lower) are shown in the bar
graph (mean 6 S.E.M., n=6).
*P,0.05,
**P,0.01 vs. sham-operated group;
#P,0.05,
##P,0.01 vs. TAC group. (C) Top panels: Representative
immunoblots from heart tissue lysates of control and TAC mice with or without [DY-9836, 10 and 20 mg/kg (DY1 or DY2)] treatment, assayed with a
phospho-CaMKIId antibody and the total CaMKIId protein. Bottom panels: Quantitative analysis of phospho-CaMKIIdB/C levels was performed by
densitometry. Data are expressed as percent values of sham-operated animals (mean 6 S.E.M., n=6).
**P,0.01,
***P,0.001 vs. sham-operated group;
##P,0.01,
###P,0.001 vs. TAC group. (D) Immunoblotting analyses of cytosolic HDAC4 (upper) and nuclear HDAC4 (lower) shown markedly
decreased levels of HDAC4 nuclear/cytosolic ratio 8 weeks after TAC and indicate that 6 weeks of DY-9836 treatment (20 mg/kg) significantly inhibits
the translocation. Right, quantitative analyses are shown in the bar graph as percentage of values of sham operated animals (mean 6 S.E.M., n=6).
The nuclear/cytosolic ratio in sham group was expressed as 1.
**P,0.01 vs. sham-operated group;
##P,0.01 vs. TAC group.
doi:10.1371/journal.pone.0024724.g003
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HDAC/MEF2-dependent signaling; and 3) the antagonism of
calmodulin restores SR Ca
2+ levels and regulates the imbalance
between NCX1 and SERCA2 by inhibiting CaMKIIdB activity,
then rescues cardiomyocytes from apoptosis and improves cardiac
function.
Numerous disturbances in the function and/or expression of
proteins involved in Ca
2+ handling have been described in the
cardiomyocytes of failing hearts. However, the contribution of
CaMKIId isoforms to transcriptional regulation, Ca
2+ handling
and cardiomyocyte apoptosis, which are factors associated with
heart failure, remains unclear. It has been shown that the over-
expression of CaMKIIdC phosphorylates Ca
2+-handling proteins,
such as RyR, PLB and L-type Ca
2+ channel complex, but has no
effect on the SERCA and NCX1 protein levels in rabbit
cardiomyocytes [21]. Cardiac over-expression of CaMKIIdB
Figure 4. The imbalance of SERCA2 and NCX1 in TAC mice is blocked by a calmodulin antagonist. Immunoblotting was carried out using
antibodies that recognized SERCA2 or NCX1 in the indicated groups. Top panels: representative immunoblots of SERCA2 (A) and NCX1 (B) in the
indicated groups. Bottom panels: densitometric analysis of relative SERCA2 (A) and NCX1 (B) levels. Densitometry values were normalized to the
average of all sham values, which corresponded to 100% (mean 6 SEM, n=6).
*P,0.05,
**P,0.01 vs. sham-operated mice;
#P,0.05,
##P,0.01 vs.
TAC-treated mice. (C) Original traces of the current in either sham or TAC adult cardiomyocytes after the application of 10 mmol/L caffeine, either
with or without DY-9836 treatment (20 mg/kg) treatment. The arrow indicates the time of caffeine administration. The amplitude of the caffeine-
induced Ca
2+ transient current can be used as an index of SR Ca
2+ content. (D) Mean amplitudes of Ca
2+ transients in TAC adult cardiomyocytes after
treatment either with or without DY-9836 treatment (20 mg/kg). F/F0; fluorescence intensity/background fluorescence levels;
**P,0.01 vs. sham cells,
##P,0.01 vs. TAC cells.
doi:10.1371/journal.pone.0024724.g004
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transgenic mice. However, the precise intracellular events in
CaMKIIdB activation that regulate Ca
2+-handling protein
expression remain to be determined. Therefore, in our present
study, we seek to address the role of CaMKIIdB in the TAC-
induced imbalance of NCX1 and SERCA2.
We first examined whether CaMKIIdB was involved in the
regulation of NCX1 expression. Notably, transfection with active
CaMKIIdB induced NCX1 protein up-regulation, as detected by
Western blot and immunocytochemical assays. Our results show
that an elevation of NCX1 occurs with activation of CaMKIIdB
during TAC-induced heart failure, possibly implying a greater
reliance on NCX1 to remove cytosolic Ca
2+ in cardiomyocytes.
Additionally, a critical role for HDACs has been proposed in the
CaMKII-mediated induction of hypertrophy [22]. In the nucleus,
HDACs interact through their N-terminus with MEF2 and
repress its transcriptional activity [22–24]. Little et al. showed
that CaMKIIdB over-expression increases MEF2 transcriptional
activity by targeting HDAC4-mediated transcriptional repression
in cardiomyocytes [22]. In the present study, we demonstrated
that a 3-fold increase in CaMKIIdB activity was accompanied by
translocation of HDAC from the nucleus to the cytosol in TAC
mice 8 weeks after surgery. This result implies that the activity of
CaMKIIdB-phosphorylated HDAC4 and the release of HDAC4-
repressed gene expression is a response to TAC, which process to
heart failure. Notably, the Ncx1 promoter contains several
Figure 5. Effect of calmodulin inhibition on TAC-induced cardiomyocyte apoptosis. TUNEL staining was used to assess the number of
apoptotic cells. Triple staining was performed: TUNEL (green), TO-PRO3 (blue), a-actinin (red). (A) Bar graph shows the increased percentage of
TUNEL-positive apoptotic cardiomyocyte nuclei (green fluorescence) 8 weeks after TAC. Scale bar=20 mm. (B) Quantification of TUNEL-positive
apoptotic cardiomyocytes in TAC mice with or without DY-9836 (20 mg/kg) treatment. Data are expressed as percentage of sham-operated animals
(mean 6 SEM, n=6).
**P,0.01 vs. sham;
##P,0.01 vs. vehicle. (C) Confocal microscopic images of double staining with anti-active caspase-3 (green
fluorescence) and anti-troponinT (red fluorescence) antibodies in the heart tissue, indicating that the predominant activation of caspase-3 occurred in
TAC mice. The number of cells showing increases in active caspase-3 was significantly reduced by DY-9836 (20 mg/kg) treatment. DAPI was used as a
counterstain, to label the cell nuclei (blue). Scale bar=20 mm.
doi:10.1371/journal.pone.0024724.g005
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factors, including two MEF2 elements at positions 2166 and 222
[25–26]. Notably, our present results suggest that the translocation
of HDAC4 via CaMKIIdB over-expression could affect the
transcriptional activation of the NCX1 exchanger. By using
MEF2c siRNA transfection, we confirmed that silencing MEF2c
induced the NCX1 expression increase in ET-treated adult
cardiomyocytes. Moreover, the present CHIP and NCX1-Luc
assay data implicated that MEF2 may act in concert with Ncx1
promoter to shape the magnitude of a NCX1-mediated signal.
Thus, we postulate that the CaMKIIdB-induced NCX1 up-
regulation is transcriptionally mediated in the TAC model, which
may include the translocation of HDACs to the cytosol and MEF2
transcripts, as well as lead to increased expression of proteins
directly involved in compensatory Ca
2+ homeostasis.
In addition, our results demonstrate an increase of NCX1 levels
in conjunction both with SERCA down-regulation in the failing
heart of TAC animals. SERCA2 transports Ca
2+ from the cytosol
to the SR of cardiomyocytes, thus maintaining the store of
releasable Ca
2+ that is necessary for contraction. We propose that
reduced SERCA2 function would be expected to cause immediate,
severe myocardial contractile dysfunction. In the present work, we
Figure 6. Effect of calmodulin inhibition on cardiac function and survival rate. (A) Representative M-mode echocardiographic images were
obtained in conscious mice 8 weeks after TAC either with or without DY-9836 (20 mg/kg) treatment. LVIDd: LV end-diastolic internal diameter; LVIDs,
LV end-systolic internal diameter; fractional shortening (FS), as follows: %FS=([LVIDd- LVIDs]/LVIDd)6100.
**P,0.01 vs. sham;
##P,0.01 vs. vehicle.
(B) The survival of mice after TAC or sham operations was monitored for 80 days. Data are expressed as percentage of sham-operated animals (mean
6 SEM, n=10).
**P,0.01 vs. sham;
#P,0.05 vs. vehicle.
doi:10.1371/journal.pone.0024724.g006
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2+ content of the SR by assessing caffeine-
induced Ca
2+ release in TAC mice. Our data demonstrated that
the Fura-2 ratio at 340/380 nm was significantly decreased by
40% in the TAC-treated adult cardiomyocytes. Likewise, the
reduced SERCA2 function was associated with an increase in
NCX1 expression, which could compensate for reduced SR Ca
2+
cycling by enhancing transsarcolemmal Ca
2+ cycling by means of
NCX during heart failure. Thus, the present data imply that the
over-expression of CaMKIIdB might induce an NCX1/SERCA2
imbalance that exacerbates the perturbation of Ca
2+ homeostasis
and causes cardiac dysfunction. Several recent studies have
indicated that SERCA2 protein degradation is stimulated by
peroxynitrite and prevented by calpain inhibitors [27]. In fact, we
reported that Ca
2+/calmodulin stimulates the degradation of
spectrin by calpain in TAC mice [16]. Thus, we propose that a
decrease in SERCA2 expression might be due to either calpain
activation or peroxynitrite formation in TAC mice.
Although hypertrophy is formed in response to hemodynamic
overload, prolonged left ventricle hypertrophy may result in
congestive heart failure. The abnormalities in calcium handling
and apoptosis of cardiac myocytes have been reported to be
involved in the transition from compensated cardiac hypertrophy
to decompensated heart failure [28–29]. Our results show that
antagonism of calmodulin significantly reduced TAC-induced
CaMKIIdB over-expression and HDAC translocalization. Treat-
ment with a calmodulin antagonist reversed the TAC-induced,
transient Ca
2+ suppression in mice, concides with inhibitory effect
on the apoptosis of cardiac myocytes in vivo and improved survival
rate. Therefore, the prolonged calmodulin antagonist treatment
might be prevents progression of cardiac hypertrophy to terminal
event (heart failure). An enhanced SR-stored Ca
2+ concentration
contributes to the cytosolic Ca
2+ homeostasis required to rescue
cardiomyocytes from apoptosis and recover contractile function.
Thus, we propose that the inhibitory effect of the calmodulin
antagonist on CaMKIIdB activity contributes to rescue from
CaMKII-mediated up-regulation of NCX1 during TAC-induced
hypertrophy, which maintains the balance of NCX1/SERCA2
and strengthens the SR Ca
2+ concentration. It has been reported
that CaMKII can directly phosphorylate cardiac SERCA2,
resulting in an increase in its enzymatic activity under physiolog-
ical conditions [30–31]. However, our present results do not
exclude the possibility that CaMKIIdB-mediated transcriptional
cross-talk and compensatory over-expression of NCX1 are
subsequently triggered upon inadequate SERCA2 expression.
Alternative approaches, such as using animals with genetically
modified SERCA2 may be important to further identify the
pathogenic process during heart failure.
In summary, our data revealed that the CaMKIIdB-mediated
aberrant expression of NCX1 and the imbalance of NCX1/
SERCA2 lead to a shift in Ca
2+ cycling towards more ICa/NCX
cycling and a reduction in SR Ca
2+ uptake and release. This result
in a reduction of the SR stored Ca
2+ concentration during TAC-
induced heart failure. The inhibition of CaMKIIdB activity and
restoration of the NCX1/SERCA2 balance by a calmodulin
antagonist partially mediates its protective effects in cardiomyo-
cytes during heart failure. The present study suggests that targeting
calmodulin as well as specifically targeting CaMKIIdB may prove
to be an effective approach for the treatment of cardiac
hypertrophy and heart failure.
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Figure S1 Effect of pharmacological inhibition of CaM-
KII and HDAC on NCX1 expression. (A) The NCX1
overexpression induced by ET is associated with CaMKIIdB
phosphorylation. (B) Effect of HDAC inhibitor on NCX1
expression following ET treatment. b-tubulin was used as the
loading control. Con, control; ET, endothelin-1; TSA, Trichos-
tatin A.
(TIF)
Figure S2 Effect of calmodulin antagonist on phosphor-
ylation of PLB in TAC mice. Representative immunoblots
from heart tissue lysates of control and TAC mice with or without
[DY-9836, 10 and 20 mg/kg (DY1 or DY2)] treatment, assayed
with phospho-PLB antibody (Thr17 or Ser16). bb-tubulin was
used as the loading control.
(TIF)
Figure S3 The calmodulin antagonist inhibited cleavage
of caspase-3 following TAC. Representative immunoblots of
cleaved caspase-3 in sham and TAC mice with or without [DY-
9836, 20 mg/kg (DY)] treatment. b-tubulin was used as the
loading control.
(TIF)
Table S1 Echocardiographic measurements in mice
with aortic banding. HR: heart rate; LV: left ventricular;
LVIDd: LV end-diastolic internal diameter; LVIDs, LV end-
systolic internal diameter; FS: LV fractional shortening. **P,0.01
vs Sham;
#P,0.05,
##P,0.01 vs TAC.
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